Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.11)
# 1,170
Out of 5,123 analysts
172
Total ratings
45.1%
Success rate
0.8%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $6.24 | +316.67% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $46.56 | +35.31% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $11.54 | +1,173.83% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $98.23 | -16.52% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $12.75 | -21.57% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $25.14 | +11.38% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.83 | +1,111.53% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $26.29 | +295.59% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.87 | +468.48% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.46 | +858.90% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $149.37 | -37.74% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $40.95 | +66.06% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $22.56 | +369.86% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $7.00 | +114.29% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $16.55 | +238.37% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $11.09 | +413.98% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $5.67 | +288.01% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.67 | +921.02% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.00 | +1,066.67% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $75.94 | -49.96% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $72.82 | -2.50% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.44 | +105.34% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $47.90 | -20.67% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.02 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.27 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.60 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $9.41 | +2,769.29% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $185.36 | - | 2 | Apr 23, 2020 |
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $6.24
Upside: +316.67%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $46.56
Upside: +35.31%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $11.54
Upside: +1,173.83%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $98.23
Upside: -16.52%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $12.75
Upside: -21.57%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $25.14
Upside: +11.38%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.83
Upside: +1,111.53%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $26.29
Upside: +295.59%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.87
Upside: +468.48%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.46
Upside: +858.90%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $149.37
Upside: -37.74%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $40.95
Upside: +66.06%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $22.56
Upside: +369.86%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $7.00
Upside: +114.29%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $16.55
Upside: +238.37%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $11.09
Upside: +413.98%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $5.67
Upside: +288.01%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.67
Upside: +921.02%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.00
Upside: +1,066.67%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $75.94
Upside: -49.96%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $72.82
Upside: -2.50%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.44
Upside: +105.34%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $47.90
Upside: -20.67%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.02
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.27
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.60
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $9.41
Upside: +2,769.29%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $185.36
Upside: -